Pictet Asset Management (UK)’s Vertex Pharmaceuticals VRTX Stock Holding History

Pictet Asset Management (UK)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$261M	Buy	1,293,145 +50,686	+4%	+$10.6M	0.28%	106
2021 Q1	$267M	Sell	1,242,459 -123,410	-9%	-$27.1M	0.32%	88
2020 Q4	$323M	Buy	1,365,869 +385,022	+39%	+$88.3M	0.42%	61
2020 Q3	$267M	Sell	980,847 -151,466	-13%	-$41.8M	0.42%	62
2020 Q2	$329M	Buy	1,132,313 +206,126	+22%	+$55.9M	0.57%	38
2020 Q1	$220M	Sell	926,187 -97,204	-9%	-$22.3M	0.47%	52
2019 Q4	$224M	Sell	1,023,391 -146,453	-13%	-$29.6M	0.4%	68
2019 Q3	$198M	Buy	1,169,844 +33,218	+3%	+$5.88M	0.42%	63
2019 Q2	$208M	Buy	1,136,626 +82,061	+8%	+$14.3M	0.45%	55
2019 Q1	$194M	Buy	1,054,565 +58,181	+6%	+$10.7M	0.43%	59
2018 Q4	$165K	Sell	996,384 -99,381	-9%	-$17.2M	0.41%	66
2018 Q3	$211M	Sell	1,095,765 -117,986	-10%	-$21M	0.45%	58
2018 Q2	$206M	Buy	1,213,751 +10,233	+0.9%	+$1.59M	0.49%	50
2018 Q1	$196M	Buy	1,203,518 +6,167	+0.5%	+$1.01M	0.48%	44
2017 Q4	$179M	Buy	1,197,351 +169,347	+16%	+$25.1M	0.46%	54
2017 Q3	$156M	Sell	1,028,004 -170,080	-14%	-$25.6M	0.44%	56
2017 Q2	$148M	Sell	1,198,084 -83,311	-7%	-$10M	0.46%	55
2017 Q1	$140M	Buy	1,281,395 +159,910	+14%	+$14.1M	0.46%	52
2016 Q4	$82.6M	Buy	1,121,485 +156,236	+16%	+$12.7M	0.31%	93
2016 Q3	$84.2M	Buy	965,249 +150,730	+19%	+$14.2M	0.32%	88
2016 Q2	$75.9M	Buy	814,519 +525,199	+182%	+$45.4M	0.3%	90
2016 Q1	$24.7M	Sell	289,320 -59,694	-17%	-$5.4M	0.11%	221
2015 Q4	$43.9M	Buy	349,014 +12,053	+4%	+$1.46M	0.19%	142
2015 Q3	$35.1M	Sell	336,961 -60,220	-15%	-$7.74M	0.15%	173
2015 Q2	$53.6M	Buy	397,181 +149,898	+61%	+$18.9M	0.22%	115
2015 Q1	$30.5M	Buy	247,283 +20,171	+9%	+$2.42M	0.13%	214
2014 Q4	$27M	Buy	227,112 +74,955	+49%	+$8.44M	0.12%	219
2014 Q3	$17.1M	Sell	152,157 -127,000	-45%	-$12.1M	0.08%	278
2014 Q2	$26.4M	Buy	279,157 +31,400	+13%	+$2.2M	0.13%	197
2014 Q1	$17.5M	Buy	247,757 +7,100	+3%	+$562K	0.09%	257
2013 Q4	$17.9M	Sell	240,657 -3,300	-1%	-$230K	0.09%	245
2013 Q3	$18.5M	Buy	243,957 +14,150	+6%	+$1.13M	0.1%	226
2013 Q2	$18.4M	Buy	+229,807	New	+$16.9M	0.11%	207

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Pictet Asset Management (UK)'s VRTX Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Vertex Pharmaceuticals (VRTX) stake by 4.1% in Q2 2021, buying an estimated $10.6M and bringing the position to 1,293,145 shares worth $261M. The position accounts for 0.28% of the portfolio, ranked #106.

Pictet Asset Management (UK) first reported a position in VRTX in Q2 2013 and has held it in 33 quarters since. The position peaked at $329M in Q2 2020. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

Pictet Asset Management (UK) held 1,293,145 shares of Vertex Pharmaceuticals worth $261M as of Q2 2021.
Pictet Asset Management (UK) bought 50,686 Vertex Pharmaceuticals shares in Q2 2021, an estimated $10.6M.
Vertex Pharmaceuticals made up 0.28% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #106 holding.
Pictet Asset Management (UK) first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 33 quarters since.
Pictet Asset Management (UK)'s Vertex Pharmaceuticals position peaked at $329M in Q2 2020.
976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.